Literature DB >> 606849

Experimental ischemic heart disease induced by thromboxane A2 in rabbits.

S Morooka, M Kobayashi, T Shimamoto.   

Abstract

How an acute ischemic attack is induced in a patient with coronary atherosclerosis is unknown and we carried out studies using thromboxane A2 (TXA2) to determine if acute myocardial ischemia and necrosis could be induced in rabbits. TXA2 was perfused through the coronary artery for 5 seconds by means of a Swan-Ganz catheter through the right common carotid artery. Significant serial changes of ST-T on ECG and hypotension were observed from 1 minute to more than 1 day after the perfusion in all 22 rabbits. The TXA2 that was composed of both aggregated platelets and prostaglandin H2 induced the same response, and such was dose dependent. The inactivated TXA2 was without effect. Seventeen of the experimental rabbits were autopsied. Histological studies of the hearts showed focal myocardial ischemia and necrosis in all rabbits except one autopsided 10 minutes after the perfusion. TXA2 is apparently capable of inducing acute myocardial ischemia and necrosis.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 606849     DOI: 10.1253/jcj.41.1373

Source DB:  PubMed          Journal:  Jpn Circ J        ISSN: 0047-1828


  3 in total

Review 1.  [Prostaglandins in cardiovascular and renal function. Biochemical, physiological and clinical findings (author's transl)].

Authors:  P C Weber; W Siess; B Scherer
Journal:  Klin Wochenschr       Date:  1979-05-03

2.  Reduction of myocardial leukocyte accumulation and myocardial infarct size following administration of BAY u3405, a thromboxane A2 receptor antagonist, in myocardial ischaemia-reperfusion injury.

Authors:  F Squadrito; M Ioculano; D Altavilla; B Zingarelli; P Canale; G M Campo; A Saitta; S Oriti; A Faggiotto; A P Caputi
Journal:  Agents Actions       Date:  1993-07

3.  AH23848, a thromboxane antagonist, suppresses ischaemia and reperfusion-induced arrhythmias in anaesthetized greyhounds.

Authors:  S J Coker; J R Parratt
Journal:  Br J Pharmacol       Date:  1985-09       Impact factor: 8.739

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.